bioAffinity Technologies, Inc. announced on October 16, 2024, that its CyPath® Lung cancer test is supported by newly published flow cytometry guidelines. A Vice President from bioAffinity served on an expert panel responsible for updating these guidelines.
The updated guidelines specifically address flow cytometry for unique biological samples, such as sputum, which is the sample type utilized by CyPath® Lung. This involvement and subsequent support validate the scientific methodology underpinning the company's diagnostic test.
This development reinforces the scientific rigor and acceptance of the technology used in CyPath® Lung, potentially aiding in broader clinical adoption and market confidence in the test's accuracy and reliability for early-stage lung cancer detection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.